The QualityStocks Daily Monday, April 15th, 2024

Today's Top 3 Investment Newsletters

SmallCapRelations(KAVL) $6.3000 +135.96%

QualityStocks(NSAV) $0.0027 +75.32%

BioMedWire(LGVN) $2.9300 +73.37%

The QualityStocks Daily Stock List

Net Savings Link (NSAV)

Investor Development Group, QualityStocks, MarketClub Analysis, Real Pennies, TheMicrocapNews, Stockgoodies, SmallCapVoice and PennyTrader Publisher reported earlier on Net Savings Link (NSAV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Net Savings Link Inc. (OTC: NSAV) is an integrated technology firm that offers turnkey technological solutions to the legal medical marijuana and hemp industries as well as other areas of the medical industry.

The firm provides its services in the United States and has its headquarters in Cresco, Pennsylvania. Net Savings Link Inc. was established on February 21, 2007.

Net Savings Link Inc. operates through the Global Distribution Corporation, which is a subsidiary it owns. Through it, the firm markets and distributes natural remedies, wellness and supplement products. The firm also offers health and wellness products, including probiotics, mineral and vitamin supplements as well as other nutraceuticals health supplements, under its Nutra Horizon brand name.

Net Savings Link Inc. is also focused on providing various services which include e-commerce and software solutions. Additionally, it provides information technology, patents and trademarks, advisory services and financial services, among others. Net Savings Link Inc. also provides hemp based beer under the brand names Angry Tiger Beer and Tiger Hemp Beer.

Net Savings Link Inc. recently announced that it had acquired a major 25% stake in SBCDF Investment Inc., which is scheduled to launch its STUX product soon. The token; SBC Token Unix X, will be marketed through all major social channels like Medium, Twitter, Telegram, Discord and Reddit. Given that SBC is a force to reckon with not only on Wall Street but also across the globe, NSAV is in for an exciting and fruitful era, which will help the company grow and avail various benefits to its shareholders.

Net Savings Link (NSAV), closed Monday's trading session at $0.0027, up 75.3247%, on 381,193,867 volume. The average volume for the last 3 months is 46.558M and the stock's 52-week low/high is $0.001/$0.00544.

Jaguar Health (JAGX)

QualityStocks, MarketBeat, BUYINS.NET, StockMarketWatch, StreetInsider, InvestorPlace, The Online Investor, StocksEarning, StockRockandRoll, Schaeffer's, PennyStockLocks, Penny Stock 101, 360wallstreet, DreamTeamNetwork, MarketClub Analysis, 247 Market News, Promotion Stock Secrets, Wealth Insider Alert, Stock Beast, The Stock Dork, Trades Of The Day and PoliticsAndMyPortfolio reported earlier on Jaguar Health (JAGX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jaguar Health Inc. (NASDAQ: JAGX) (FRA: 1JA2) is a commercial-stage pharmaceuticals firm that is focused on developing and commercializing gastrointestinal products for animals and human prescription use and non-prescription gastrointestinal animal products.

Jaguar Health has its headquarters in San Francisco, California and serves the human and animal health markets across the globe. The firm was established on June 6, 2013 by Lisa A. Conte.

Through its Napo Pharmaceuticals Inc. subsidiary, Jaguar Health Inc. develops and commercializes proprietary human gastrointestinal products. This is in addition to operating through 2 segments: Animal health segment and Human health segment. The former segment commercializes non-prescription and prescription products for production and companion animals while the latter segment develops human products and advertises one of the firm’s products called Mytesi which is used to provide symptomatic relief of non-infectious diarrhea in adults on ARV therapy for HIV/AIDS.

Jaguar Health Inc.’s human products include a crofelemer formulation which is currently undergoing a phase 2 clinical trial for the treatment of irritable bowel, functional/idiopathic diarrhea, congenital diarrheal disorder and short bowel syndrome; crofelemer, which is in its phase 3 clinical trials for supportive care for inflammatory bowel disease and treatment of diarrhea associated with cancer therapy. The firm’s animal products include Neonorm Foal and Neonorm Calf, as well as a non-prescription product for gut health in equine athletes known as Equilevia and an animal prescription drug candidate indicated for the treatment of diarrhea in dogs induced by chemotherapy, called Canalevia.

Jaguar Health Inc. recently incorporated its Napo EU subsidiary in anticipation of its merger with Italian Dragon SPAC, which will broaden the firm’s consumer base overseas and boost growth. The subsidiary will help address the increasing burden of inflammatory diarrhea that has been linked to long-hauler syndrome in the post-coronavirus patient population over in Europe.

Jaguar Health (JAGX), closed Monday's trading session at $0.1188, up 31.5615%, on 115,111,213 volume. The average volume for the last 3 months is 2.324M and the stock's 52-week low/high is $0.0512/$1.22.

Soligenix (SNGX)

PCG Advisory, QualityStocks, Streetwise Reports, RedChip, StockMarketWatch, MarketBeat, TradersPro, TraderPower, AllPennyStocks, SmallCapVoice, FeedBlitz, PennyStocks24, Stockgoodies, MarketClub Analysis, BUYINS.NET, The Street, Marketbeat.com, OTC Markets Group, Pennybuster, PennyStockDD, PennyStockProphet, HotOTC, PennyStockScholar, PennyTrader Publisher, alert, ProActive Capital, Zacks, Schaeffer's, Small Caps, Stock Beast, Stock Rich, StockEgg, StockOodles, UltimatePennyStock and Pick Alerts reported earlier on Soligenix (SNGX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Soligenix Inc. (NASDAQ: SNGX) (FRA: DOA3) is a late-stage biopharmaceutical firm that is engaged in the development and commercialization of products to treat rare ailments like gastrointestinal graft-versus-host disease in the U.S. It also develops vaccines for civilian and military applications.

The firm has its headquarters in Princeton, New Jersey and was founded in 1987. Prior to its name change in 2009, the firm was known as DOR BioPharma Inc. It operates as part of the healthcare sector, under the biotech and pharma sub-industry.

The company operates through the public health solutions and specialized biotherapeutics segments. The former segment is involved in developing a vaccine candidate indicated for coronavirus prevention dubbed CiVax; a technology designed for vaccine thermo-stabilization called ThermoVax; a drug formulation indicated for treating antibiotic-resistant and emerging infectious ailments like Ebola dubbed SGX943, which is in pre-clinical stage and a ricin toxin candidate dubbed RiVax, which recently concluded phase 1 clinical trials. On the other hand, the latter segment provides proprietary oral formulations which recently concluded phase 1 and 2 clinical trials evaluating their effectiveness in treating gastrointestinal disorders characterized by serious inflammation. These include candidates developed for the treatment of pediatric Crohn’s disease and acute radiation enteritis dubbed SGX203 and SGX201, respectively.

The enterprise was recently awarded a patent for its (SGX301) HyBryte formulation. This move not only expands, protects and strengthens its synthetic hypericin patent estate but also brings them closer to marketing approval and commercialization of their SGX301 candidate, which has been indicated for CTCL, a class of non-Hodgkin’s lymphoma.

Soligenix (SNGX), closed Monday's trading session at $0.47, up 21.7301%, on 135,037,373 volume. The average volume for the last 3 months is 90,648 and the stock's 52-week low/high is $0.3705/$4.20.

Great Pacific Gold (FSXLF)

InvestorPlace, QualityStocks and The Online Investor reported earlier on Great Pacific Gold (FSXLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Great Pacific Gold Corp (OTCQX: FSXLF) (CVE: GPAC) (FRA: V3H) is a junior exploration firm that is focused on acquiring and exploring for gold and copper deposits in Australia and Papua New Guinea.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2019, on July 22nd. Prior to its name change in September 2023, the firm was known as Fosterville South Exploration Limited. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates a significant 2,166km2 mineral exploration land package in Papua New Guinea (PNG). The land package has 3 main projects, which include three licenses (ELs) and multiple exploration license applications (ELAs). It includes both early-stage and advanced-stage exploration targets with epithermal vein and porphyry-style mineralization potential present. The projects include Arau, Kesar Creekand Wild Dog. The Arau Project comprises of one granted exploration license, EL 2651; and one exploration license application, ELA 2715, located in the Kainantu region. The Kesar Creek Project includes one granted exploration license, EL 2711, and is located 10km west of the K92 Gold Mine owned and operated by K92 Mining Inc. The Wild Dog Project comprises of one granted exploration license, EL 2761; and one exploration license application, ELA 2516, located on the island of New Britain and about 50km southwest of Rabaul and Kokopo, PNG.

The enterprise, which recently concluded its acquisition of Wild Dog Resources Inc., remains committed to diversifying its portfolio with high-quality gold and copper assets and growing through the execution of its well thought out drill programs. This may in turn help create additional value for its stakeholders.

Great Pacific Gold (FSXLF), closed Monday's trading session at $0.98, up 12.6566%, on 1,091,337 volume. The average volume for the last 3 months is 345,504 and the stock's 52-week low/high is $0.24/$0.995.

Jushi Holdings (JUSHF)

QualityStocks, MarketBeat, TradersPro, Daily Trade Alert, The Street, Prism MarketView and InvestorPlace reported earlier on Jushi Holdings (JUSHF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jushi Holdings Inc. (OTCQX: JUSHF) (CNSX: JUSH) is a vertically integrated multi-state cannabis and hemp operator that is focused on cultivating, processing, retailing and distributing medical and adult-use products.

The firm has its headquarters in Boca Raton, Florida and was incorporated in January 2018 by Jon Barack, Erich Mauff and Jim Cacioppo. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm primarily serves consumers in the United States.

The company operates a diverse portfolio of branded cannabis and hemp-derived assets, built upon opportunistic acquisitions, distressed deals and competitive applications. It strives to maximize shareholder value while delivering high premium products across all levels of the cannabis and hemp ecosystem.

The enterprise focuses on building a portfolio of cannabis assets in various jurisdictions in Ohio, Pennsylvania, Virginia, Nevada, Illinois, California and Massachusetts. It also provides hemp-based CBD products, including cannabis dry flower, edibles, vaporizer forms of cannabis, cannabis oil in capsules, tinctures, cannabis in topical products, and other cannabis products, as well as vape cartridges, concentrates and disposables under The Bank, Hijinks, The Lab, Nira+ Medicinals, Tasteology and Sèchè brands. In addition, the enterprise operates medical cannabis dispensaries under the NuLeaf, BEYOND/HELLO and Nature's Remedy brands.

The firm, which recently announced its latest financial results, has opened a 6th Beyond HelloTM medical cannabis dispensary in Woodbridge, Virginia. This move may help extend the firm’s consumer reach while also bringing in additional revenues.

Jushi Holdings (JUSHF), closed Monday's trading session at $0.6696, up 9.7705%, on 313,917 volume. The average volume for the last 3 months is 460,512 and the stock's 52-week low/high is $0.3495/$1.09.

Magnachip Semiconductor (MX)

Super Stock Picker, Zacks, MarketBeat, The Street, StockMarketWatch, StreetInsider, BUYINS.NET, Marketbeat.com, Louis Navellier, Schaeffer's, Barchart, TradersPro, Market Intelligence Center Alert, Investopedia, StreetAuthority Daily, Trades Of The Day, Hit and Run Candle Sticks, InvestorPlace, Early Bird, Daily Trade Alert, MarketClub Analysis, QualityStocks, Stockhouse, Street Insider, TopStockAnalysts, Wealth Insider Alert, WStreet Market Commentary and Penny Sleuth reported earlier on Magnachip Semiconductor (MX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Magnachip Semiconductor Corporation (NYSE: MX) (FRA: SMG) is a company focused on designing, manufacturing and supplying analog and mixed-signal semiconductor platform solutions for the Internet of Things, communications, computing, consumer, automotive and industrial applications.

The firm has its headquarters in Cheongju, South Korea and was incorporated in 2003, on November 26th. It operates as part of the semiconductors industry, under the technology sector. The firm serves consumers around the globe.

The enterprise offers display solutions, which include source and gate drivers and timing controllers that cover a range of flat panel displays used in entertainment devices, mobile communications, automotive, notebook PCs, monitors, tablet PC and TVs applied with liquid crystal display, organic light emitting diodes (OLED), and micro light emitting diode (Micro LED) panels. It also provides insulated-gate bipolar transistors, metal oxide semiconductor field-effect transistors, DC-DC converters, AC-DC converters, LED drivers, power management integrated circuits, and regulators for a range of devices including tablet PCs, televisions, mobile phones, smartphones, desktop PCs, wearable devices, notebooks, and other consumer electronics, as well as for e-bikes, power suppliers, LED lighting, photovoltaic inverters, and motor drives; and OLED display driver integrated circuit products. The enterprise serves computing, consumer, communication, automotive and industrial electronics OEMs, original design manufacturers, and electronics manufacturing services firms, as well as subsystem designers in Europe, the United States, and the Asia Pacific. It sells its products through a network of agents and distributors as well as through a direct sales force.

The company, which recently released its latest financial results, is focused on growing its revenues and creating long-term value for its shareholders. This may positively influence Magnachip’s overall growth.

Magnachip Semiconductor (MX), closed Monday's trading session at $5.1, off by 3.0418%, on 297,297 volume. The average volume for the last 3 months is 48.858M and the stock's 52-week low/high is $5.095/$11.68.

Intel Corp. (INTC)

FreeRealTime, The Street, InvestorPlace, Kiplinger Today, StockMarketWatch, Schaeffer's, StreetAuthority Daily, Zacks, The Online Investor, MarketClub Analysis, Investopedia, StreetInsider, Daily Trade Alert, Trades Of The Day, TopStockAnalysts, Money Morning, MarketBeat, CNBC Breaking News, Barchart, Dividend Opportunities, PROFIT CONFIDENTIAL, StocksEarning, Market Intelligence Center Alert, InvestorGuide, SmarTrend Newsletters, Early Bird, Louis Navellier, INO Market Report, The Motley Fool, Street Insider, TheStockAdvisors, Daily Profit, ProfitableTrading, Daily Wealth, INO.com Market Report, Uncommon Wisdom, Wyatt Investment Research, Top Pros' Top Picks, The Wealth Report, internetnews, TheStockAdvisor, TradingAuthority Daily, Trading Markets, Wealth Insider Alert, internet, Insider Wealth Alert, Investor Guide, SiliconValley, Marketbeat.com, StrategicTechInvestor, Money and Markets, Money Wealth Matters, CustomerService, The Best Newsletters, MarketWatch, Investors Alley, The Street Report, Market FN, WStreet Market Commentary, StreetAlerts, DrStockPick, Cabot Wealth, GorillaTrades, Wealth Daily, IT News Daily, The Growth Stock Wire, Investor Update, Daily Dividends, DividendStocks, Daily Markets, TradingMarkets, Wall Street Daily, Investing Daily, Eagle Financial Publications, AllPennyStocks, Forbes, Trading Tips, StockHotTips, CRWEWallStreet, ChartAdvisor, CRWEFinance, InsiderTrades, Greenbackers, Stockhouse, Trade of the Week, Leeb's Market Forecast, Investment U, PennyOmega, Trading Concepts, PennyToBuck, BestOtc, CRWEPicks, Coattail Investor, TipRanks, QualityStocks, Dynamic Wealth Report, FeedBlitz, InvestmentHouse, Super Stock Investor, Market Authority, The Night Owl, SmallCap Network, Energy and Capital, SwingTradeOnline, FeedTheBull, StockEarnings, Darwin Investing Network, Market Intelligence Center, SmallCapVoice, Taipan Daily, Wealthpire Inc., wyatt research newsletter, FNNO Newsletters, iStockAnalyst, Wall Street Elite, Trader Prep, Investment House, OnTheMar, Market Wrap Daily, The Dividend Guy, SmallCapNetwork, Investing Lab, Stock Gumshoe, Quant Ratings Team, Penny Stock Buzz, Jon Markman’s Pivotal Point, InvestorsObserver Team, Inside Investing Daily, The Stock Enthusiast, Investing Signal, 24/7 Trader, Willy Wizard, InvestorIntel, Hit and Run Candle Sticks, Jim Cramer, Stocks in the Spotlight, All Star Investor, Wall Street Resources, Wall Street Greek, Bloomfield Investment Club, Total Wealth, TheOptionSpecialist, The Weekly Options Trader, The Trading Report, The Daily Market Alert, Shah's Insights & Indictments, StockTwits, Lebed.biz, Equities.com, Market Pulse, FlintFreeFinance, Millennium-Traders, Short Term Wealth, Earnings360, PennyStockOracle, Profitable Trader Authority, Early to Rise and BUYINS.NET reported earlier on Intel Corp. (INTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Earlier this week, Tesla CEO Elon Musk forecasted that by 2025 or 2026, artificial intelligence would have gotten smarter than humans. In an extensive interview on X spaces, the billionaire told Nicolai Tangen of Norway Wealth Fund that artificial intelligence was constrained by electricity’s limited availability.

Musk then revealed that by next month, the new version of Grok would be trained. Grok is an artificial intelligence chatbot designed by Musk’s xAI start-up. He founded xAI in 2023 as a challenger to OpenAI, which he’s taken to court for casting aside its original mission to develop artificial intelligence for humanity’s benefit instead of profit.

Musk, who served as an initial board member in OpenAI, noted that a shortage of advanced chips was impeding the training of Grok’s latest model. OpenAI, an artificial intelligence research organization, has denied the billionaire’s allegations.

The Grok 2 model needed about 20,000 H100 graphic processing units from Nvidia to fully function, with Musk noting that the latest model and any other moving forward would need 100,000 of the same chips to function. The billionaire then observed that while a chip shortage was a big limitation on artificial intelligence development currently, the supply of electricity would be pivotal in the next year or two.

When asked about the timeline for artificial general intelligence (AGI) development, Musk theorized that in a year or two, AGI would be smarter than the smartest person. With regard to electric vehicles, Musk claimed that auto manufacturers in China were the most competitive globally. He added that Chinese auto manufacturers also posed the toughest competitive challenge to his company.

Musk has, in the past, warned that Chinese competitors will destroy their rivals globally without trade barriers. Thus far, competition from Chinese players has led Tesla to scrap its plan to begin manufacturing low-cost family cars. This inexpensive car, which investors hoped would drive Tesla’s growth into a mass-market manufacturer of electric vehicles, had been in the works since the company’s inception. In 2006, Musk had highlighted in his initial master plan that Tesla would enter the market manufacturing luxury models first then use its profits to fund development of a low-cost vehicle.

During the recent interview, the billionaire also discussed a strike against Tesla in Sweden, noting that he believed the storm had passed on that front. Tangen revealed that the sovereign wealth fund, which holds a good chunk of Tesla shares, had met with Musk in March and gotten an update on the situation.

As enterprises such as Intel Corp. (NASDAQ: INTC) scale up their manufacturing of the hardware needed to power the AI revolution, Elon Musk’s prediction that AI will outsmart humans less than two years from now could become a reality.

Intel Corp. (INTC), closed Monday's trading session at $36.31, up 1.7372%, on 50,751,563 volume. The average volume for the last 3 months is 924,454 and the stock's 52-week low/high is $26.855/$51.28.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, QualityStocks, Kiplinger Today, MarketBeat, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, The Online Investor, MarketClub Analysis, Profit Trends, Wealth Insider Alert, StreetInsider, Early Bird, Trading For Keeps, Trades Of The Day, The Street, Prism MarketView, TradersPro, Zacks, Schaeffer's, Investment U, StreetAuthority Daily, wyatt research newsletter, Daily Profit, CFN Media Group and Wyatt Investment Research reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In the last two months, federal officials have seized hundreds of pounds of cannabis intended for retail sale from state-licensed businesses in New Mexico. This is in addition to detaining workers in the industry in what appears to be an escalation of enforcement of prohibition at the national level.

This is despite the fact that the federal government has thus far avoided interfering with the implementation of legalization laws at the state level.

Reports from cannabis businesses in the state show that more than 12 seizures by U.S. Customs and Border Protection (CBP) have occurred, particularly at checkpoints inside the state of New Mexico. CBP is allowed to conduct its activities within 100 miles of the United States border. This move by the feds has perplexed many, especially because New Mexico launched recreational cannabis sales in 2022 with operators revealing that they have had no issues transporting their products to retailers and testing facilities across the state.

In a recent interview, the executive director of the state’s Cannabis Chamber of Commerce, Ben Lewinger, revealed that numerous successful marijuana producers and manufacturers operated near the CBP checkpoints. Lewinger explained that most roads taken from the southern to northern parts of the state required individuals to pass through a checkpoint, noting that this made it impossible for operators in New Mexico’s southern region to transport their products to the northern or central parts of the state.

Since February, CBP has carried out no less than 13 stops and seizures of state-legal cannabis products, particularly around the Las Cruces area. Lewinger believes that this number is underreported, particularly since most people still have some stigma and fear over cannabis and its use.

Matt Chadwick, Top Crop Cannabis Co. CEO, revealed that in February his employee was delivering 22 pounds of product with a total value of roughly $139,000 to the company’s locations in Albuquerque when he was stopped at a checkpoint. A dog then alerted CBP agents to the smell, leading to a secondary inspection.

Chadwick revealed that the employee ended up being detained for a number of hours before being released with no documentation and none of the product. When the employee inquired about the product, an agent informed him that he would receive information on how he would be reimbursed for the seized product via mail.

Other affected businesses include Schwazze, which did receive documentation on its seized product but has no hope for possible reimbursement.

Industry actors such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) will be waiting to hear what explanation the feds give for seizing cannabis products from licensed companies going about their legitimate state-sanctioned activities.

Curaleaf Holdings Inc. (CURLF), closed Monday's trading session at $4.83, even for the day, on 447,130 volume. The average volume for the last 3 months is 887,291 and the stock's 52-week low/high is $2.19/$5.91.

Warrior Met Coal Inc. (HCC)

QualityStocks, MarketBeat, The Online Investor, DividendStocks, INO.com Market Report, StreetInsider, Zacks, TradersPro, MiningNewsWire, The Street, Daily Trade Alert, Trades Of The Day, BUYINS.NET, StockMarketWatch, InvestorPlace, Schaeffer's, StreetAuthority Daily, MarketClub Analysis, Cabot Wealth, CRWEFinance, Dividend Report, FreeRealTime, InsiderTrades, Market Intelligence Center Alert, AllPennyStocks, Street Insider, SmarTrend Newsletters and TopStockAnalysts reported earlier on Warrior Met Coal Inc. (HCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Earlier this week, GE Vernova announced that it would provide a H65 generator and a 7HA.02 gas turbine to Korea Western Power Co’s Gongju-si power station in the province of Chungcheongnam-do.  Korea Western Power Co (KOWEPO) operates as a subsidiary of Korea Electric Power Corp. KOWEPO is spearheading a 500MW project as it transitions to using natural gas by 2027. At the moment, however, the station is powered using coal.

GE Vernova is part of a group developing the project, together with Daewoo E&C, an engineering, construction and procurement company based in Korea. The project will use hydrogen in its fuel mixture. The gaseous component will be determined by the scale of future hydrogen production in South Korea.

Recent data from the U.S. Energy Information Administration shows that natural-gas- and coal-fired generation generates roughly two-thirds of electricity in South Korea. Nuclear power makes up about 26% of remaining total power generated. South Korea relies on imports of liquefied natural gas and coal because it doesn’t produce any fossil fuels domestically.

In a news release, a KOWEPO representative explained that the new power plant would increase production capacity and, in turn, power supply security in the country while phasing out generation of power using coal. The statement added that the power plant would also increase capacity to dispatch power quickly in response to fluctuations in the grid.

Construction of the new facility is expected to start in 2025, with officials noting this week that burning natural gas at the plant could decrease carbon emissions by almost 60% and reduce emissions of sulfur oxides (SOx), nitrogen oxides (NOx), particulate matter and mercury. This aligns with South Korea’s national goal to achieve carbon neutrality by 2050 through the deployment of green hydrogen and renewables at large scale. The country is also planning to retire 30 or more coal-fired plants by 2034 as part of its phase out plan.

In a statement, GE Vernova’s Ramesh Singaram stated that the company was proud to support a lower carbon future in the country and was committed to furnishing KOWEPO with its advanced turbine technology to accelerate the phasing out of coal and adopt lower-carbon gas-based power generation using hydrogen. The Gongju-si power plant is expected to be among the most flexible and efficient plants in the country when it commences operations. GE Vernova has operated in the east Asian country since the 1970s and has a strong presence with gas turbines that can generate more than 14GW of electricity across the nation.

As more companies whose plants have been fueled by coal make plans to switch to energy sources such as natural gas with fewer emissions, the writing is on the wall for coal companies such as Warrior Met Coal Inc. (NYSE: HCC). These trends indicate that coal is increasingly growing out of favor around the world and its use could soon decline to levels that render the industry obsolete.

Warrior Met Coal Inc. (HCC), closed Monday's trading session at $62.82, up 0.495921%, on 590,655 volume. The average volume for the last 3 months is 34.902M and the stock's 52-week low/high is $31.9713/$69.97.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, StockEarnings, Schaeffer's, QualityStocks, The Street, MarketBeat, Early Bird, MarketClub Analysis, GreenCarStocks, StocksEarning, Investopedia, INO Market Report, Daily Trade Alert, Trades Of The Day, Kiplinger Today, Money Wealth Matters, The Online Investor, Louis Navellier, The Wealth Report, Zacks, DividendStocks, BillionDollarClub, The Night Owl, Cabot Wealth, Wealth Whisperer, Green Energy Stocks, Top Pros’ Top Picks, InvestorsUnderground, AllPennyStocks, The Stock Dork, Smartmoneytrading and InsiderTrades reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Once dubbed the “Tesla killer,” electric vehicle start-up Lucid Motors (NASDAQ: LCID) was expected to push Tesla to the ropes and threaten the EV giant’s global supremacy. Lucid seduced investors with the idea of luxury electric cars that offered better performance than the Porsche Tycan, Maybach S-Class levels of ambience and more range than any other battery electric vehicle (BEV) on the globe.

With its headquarters expected to be in mid-California, Lucid’s main base of operations would be close enough to Meta to poach some of its top coding experts while providing the startup with great weather all year round. As Tesla was still headquartered in California at the time, Lucid would also be able to steal talent from the pioneering EV maker in its quest to surpass Tesla and be the world’s largest electric vehicle producer.

However, Lucid’s overly ambitious plans crashed and burned in the years after the startup joined the EV game, and the company has never gotten close to reaching Tesla’s sales numbers, let alone surpassing them. Lucid Motors planned to produce up to 14,000 of the Lucid Air Saloon in 2023, but the startup only manufactured a paltry 8,428 electric vehicles by the end of the year. The first three quarters of the year also saw Lucid register a massive $2.17 billion loss, $630 million of it lost from July to September.

Several years after it was initially launched, Lucid Motors is struggling to fulfill promises made to investors and has barely made a mark on the extremely competitive electric vehicle sector. Chief financial officer Sherry House stepped down from her position in late 2023, dealing another blow to a company that struggled to stay afloat and boost its production output for several years, forcing it to name vice president of accounting and principal accounting officer Gagan Dhingra as interim CFO.

House’s resignation came weeks after Lucid Motors unveiled the Gravity SUV and only days after the beleaguered EV maker was struck from the NASDAQ-100 index. Although House said she was confident in the company’s future, things aren’t looking good for Lucid, especially with electric vehicle demand cooling in recent months amid rising interest rates, high living costs and stiff competition.

Consequently, established automakers such as Ford and General Motors have scaled back their ambitious plans to fully electrify their vehicle lineups over the next decade in favor of more modest plans. Extreme competition from Chinese EV makers also forced Tesla to cut electric vehicle prices in most major markets, causing both new and used EV prices to fall across the board.

Lucid is now testing the Gravity SUV and is constructing a massive facility in Arizona that will reportedly produce 400,000 EVs per annum; the company is also finishing up a manufacturing center in Saudi Arabia that will produce 155,000 electric cars.

Lucid Motors (LCID), closed Monday's trading session at $2.43, off by 2.4096%, on 19,381,490 volume. The average volume for the last 3 months is 663,267 and the stock's 52-week low/high is $2.40/$8.37.

Stronghold Digital Mining Inc. (SDIG)

QualityStocks, RedChip, MarketBeat, Investor News, InvestorPlace, Real Pennies, SmallCapVoice, StockEarnings, Zacks, Early Bird, OTC Markets Group, StockPicksNYC, StocksEarning, The Online Investor, InsiderTrades and Prism MarketView reported earlier on Stronghold Digital Mining Inc. (SDIG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A Binance executive has entered a plea of innocence regarding allegations of money laundering in a Nigerian court. Tigran Gambaryan, a United States citizen, was apprehended in February alongside his coworker Nadeem Anjarwalla, who holds dual British-Kenyan nationality. Anjarwalla escaped custody two weeks ago, and his current location remains unknown.

Gambaryan, during his court appearance on April 8, 2024, refuted the five charges of money laundering brought forth by Nigeria’s Economic and Financial Crimes Commission (EFCC). Subsequently, he was transferred to the Kuje Correctional Center in Abuja, Nigeria’s capital. The correctional center has previously housed a spectrum of detainees, from militants to politicians. Gambaryan and Anjarwalla had previously been confined in an undisclosed location.

Following the proceedings, Yuki, Gambaryan’s wife, expressed deep dismay, lamenting her husband’s detention in a facility known for detaining “murderers and terrorists.” She condemned the treatment of her husband, whom she asserts is entirely innocent.

A spokesperson for Binance dismissed the allegations against Gambaryan as groundless, noting his lack of decision-making authority within the company. The spokesperson expressed disappointment over Gambaryan’s continued detention.

The EFCC accused Binance along with Gambaryan and Anjarwalla of money laundering of $35.4 million. Gambaryan, Binance’s head of financial crime compliance, and Anjarwalla, serving as its regional manager in Africa, were detained upon their arrival in Nigeria for discussions regarding the exchange’s activities in the country. Subsequently, Binance was ordered to pay a hefty fine of $10 billion for alleged currency manipulation and speculation, which purportedly contributed to the devaluation of Nigeria’s currency, the naira.

The depreciation of the naira, coupled with escalating living costs and food inflation, has precipitated an economic crisis in the country.

Binance is not an isolated case. Nigerian regulators have intensified their scrutiny of crypto platforms, suspecting their involvement in terrorism financing and money laundering.

In addition to money laundering allegations, Binance, Gambaryan and Anjarwalla face tax-evasion charges comprising four counts, leveled by the Federal Inland Revenue Service (FIRS). Following Anjarwalla’s escape from the country, Nigerian authorities stated that he absconded using a fake passport. However, a source close to his family said that he exited the country “through legal channels.”

The authorities stated that they were collaborating with Interpol to secure an international arrest warrant for Anjarwalla. However, as of the latest update, Anjarwalla is not listed on Interpol’s red notice for globally wanted fugitives.

The arrest of these two officials during their trip to Nigeria is likely to be of concern to other crypto industry players such as Stronghold Digital Mining Inc. (NASDAQ: SDIG) because it raises risks for traveling executives who are conducting legitimate company business.

Stronghold Digital Mining Inc. (SDIG), closed Monday's trading session at $2.23, off by 29.2063%, on 1,363,636 volume. The average volume for the last 3 months is 134,343 and the stock's 52-week low/high is $2.15/$12.50.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, BioMedWire, PsychedelicNewsWire, MarketClub Analysis, StockEarnings, Penny Dreamers, InvestorPlace, CFN Media Group, bullseyeoptiontrading, Broad Street and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is reporting on its investment in Celly Nutrition Corp. According to the report, FSA entered into a loan-amending agreement with Celly Nu that increased the principal of a previously announced term loan by $300,000, from $1 million to $1.3 million. Celly Nu is a privately held Canadian company launching an innovative beverage product that can assist in expediting alcohol metabolism and faster recovery from alcohol consumption. The announcement noted that the interest payment due on the first annual anniversary of the loan would be deferred and become payable on the second annual anniversary together with the interest payment due on that date; the loan bears interest at 10% per annum payable on each anniversary and expires July 31, 2026. The company plans on using funds from the loan for product manufacturing of unbuzzd(TM), a scientifically formulated blend of vitamins, minerals and herbs designed to enhance mental alertness, expedite alcohol metabolism and facilitate rapid recovery from alcohol consumption. “This expanded loan agreement is one more step by Celly Nu and FSD Pharma in bringing this innovative new product to market across North America,” said Celly Nutrition CEO John Duffy.

To view the full press release, visit https://ibn.fm/oQM4J

About FSD Pharma Inc.

FSD is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. FSD Pharma has also licensed unbuzzd(TM), a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp; FSD Pharma is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD Pharma continues its R&D activities to develop novel formulations for alcohol-misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD Pharma also maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property. For more information about the company, please visit www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Monday's trading session at $0.5229, off by 12.3974%, on 77,648 volume. The average volume for the last 3 months is 3,461 and the stock's 52-week low/high is $0.51/$1.8967.

The QualityStocks Company Corner

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

The U.S. Department of Justice (DOJ) is once again urging a federal court to reject a lawsuit filed by prominent cannabis companies aiming to halt the enforcement of federal laws against marijuana activities permitted by states. According to the government, the legalization of cannabis encourages tourism across state lines, giving it the constitutional authority to intervene. In its recent submission to the United States District Court of Massachusetts, the DOJ disapproved assertions made by marijuana businesses, refuting the notion that federal policies contradict enforcement practices. It further contended that the plaintiffs lacked standing to file the complaint. It would be interesting to hear the views about the DOJ position in this case from companies that have an interest in the cannabis industry such as Astrotech Corp. (NASDAQ: ASTC) since the federal department seems determined to do everything in its power to block any calls for marijuana law reform.

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.

Subsidiaries

Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Monday's trading session at $9.69, up 0.103306%, on 1,581 volume. The average volume for the last 3 months is 1.852M and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the company's CLEAR MIND Phase 2a study results. A Phase 2a randomized clinical trial, CLEAR-MIND is evaluating Lomecel-B(TM) in mild Alzheimer's disease. In addition to the study results, Longeveron has been accepted for a poster presentation at the 2024 Alzheimer's Association International Conference ("AAIC") taking place online and in Philadelphia, Pennsylvania, from July 28 – August 1, 2024. "We are extremely excited to share the full study results of our CLEAR-MIND trial at the AAIC meeting this year and have the opportunity to present at the leading forum for Alzheimer's disease clinical investigation," said Wa'el Hashad, CEO of Longeveron.

To view the full press release, visit https://ibn.fm/yklZM

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Monday's trading session at $2.93, up 73.3728%, on 57,100,128 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $15.11/$.

Recent News

Zoned Properties Inc. (OTCQB: ZDPY)

The QualityStocks Daily Newsletter would like to spotlightFathom Zoned Properties Inc. (OTCQB: ZDPY).

There are more cannabis dispensaries than McDonald's outlets in the United States today, a reflection of the ongoing shift in consumer trends and legal frameworks across America

Over 74% of Americans now live in a state which permits either, the medical or recreational consumption of marijuana

Zoned Properties has emerged as an early leader in facilitating the transition of U.S. cannabis businesses towards developing a physical retail footprint with a portfolio of cannabis-focused investment properties across Arizona, Michigan and Illinois

The company recently updated the market with the release of a positive set of FY 2023 annual results

In 2019, McDonald's launched a nationwide marketing campaign across the nation entitled, ‘Around the world is now around the corner' (https://cnw.fm/BrsKg). Celebrating the fact that some of the chain's most popular global offerings were now easily found in everyone's local participating McDonald's, the campaign hinged on the seemingly ubiquitous availability and presence of the restaurant's outlets across the United States. Remarkably and in representation of America's rapidly changing attitude towards cannabis today, the number of cannabis dispensaries dotted across the United States have now surpassed those of McDonald's Corp restaurants, a reflection of the United States' dramatic and ongoing evolution in consumer trends and legal frameworks. Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States, has been amongst the early leaders in facilitating the transition of the cannabis industry towards the physical retail space. The company maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois; with each of its leased properties occupied by commercial cannabis-linked businesses, the company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years. In addition to maintaining four properties leased and repurposed as regulated cannabis retail dispensaries, the company presently leases two properties which are operated as regulated cannabis cultivation and processing facilities.

Zoned Properties Inc. (OTCQB: ZDPY) is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to best-in-class cannabis retailers.

The company is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development process, including a commercial real estate brokerage and a real estate advisory practice.

With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value and then works to acquire the properties while securing long-term, absolute-net leases.

Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law.

The company is headquartered in Scottsdale, Arizona.

Portfolio

The company’s investment properties are located in Arizona, Michigan and Illinois, with 100% occupancy and a weighted average lease term over 10 years. Each of the company’s leased properties is occupied by a commercial cannabis tenant. The company is expecting rental revenue from its property investment portfolio of greater than $2.5 million in calendar-year 2024.

Zoned Properties maintains a portfolio of properties that it owns, develops and leases. As of February 2024, the company leases land and/or building space at the six properties in its portfolio to licensed and regulated cannabis tenants in areas with established cannabis regulations and zoning procedures. Four of the leased properties are zoned and permitted as regulated cannabis retail dispensaries, and two of the leased properties are zoned and permitted as regulated cannabis cultivation and processing facilities.

The company considers the two cultivation sites in its portfolio as legacy properties and may consider selling or leveraging those properties to unlock equity and create capital availability in the future. The Zoned Properties investment thesis has evolved over the years as the cannabis industry has emerged, and the company is currently focused on investing capital into direct-to-consumer properties, located in state-markets with robust cannabis consumer demand in the industry.

Zoned Properties is in pursuit of property acquisitions that can be characterized as consumer-facing, retail dispensary properties that are positioned to be leased to retail dispensary cannabis tenants under net leasing structures. As of September 2023, the company has agreements in place to acquire new investment properties with new cannabis tenants located in Arizona, Missouri and Illinois. The company plans to initiate and target its investment process in Ohio and Maryland.

With a strategic shift in focus to direct-to-consumer real estate that is leased to best-in-class cannabis retailers in the industry, the company will continue to utilize its competitive edge when identifying excellent investment properties. Zoned Properties has a full pipeline of acquisition prospects and continues to utilize an extremely disciplined capital allocation approach.

Market Opportunity

According to MJBizDaily, a publication that has covered the North American cannabis business since 2011, combined U.S. medical and recreational cannabis sales were estimated at approximately $33.6 billion at the end of 2023, largely driven by the opening of new adult-use markets.

The publication projects that combined U.S. retail cannabis sales will reach upwards of $53.5 billion by 2027, according to an analysis published in its volume of cannabis market research, the MJBiz Factbook.

As of February 2024, 38 U.S. states had legalized medical, recreational or other limited use of cannabis. The Pew Research Center reports that, in January 2023, there were more than 11,000 licensed cannabis dispensaries in the U.S. In addition, global research firm IBISWorld reports that more than 40,000 U.S. localities have adopted regulations governing cannabis usage, production, processing and/or dispensing.

Management Team

Bryan McLaren is the Chairman and CEO of Zoned Properties. Previously, he worked as a Sustainability Consultant for Waste Management Inc., where he led the strategic development and operational implementation of zero-waste programs for clients. He was also appointed as a city Sustainability Commissioner. He holds a bachelor’s degree in business administration from the University of San Diego, a master’s degree in sustainable development from Northern Arizona University, an executive master’s degree in business leadership from Arizona State and an MBA with a specialty in sustainable development.

Berekk Blackwell is the President and COO of Zoned Properties. He previously spent time in developing domestic and international markets for Kahala Brands, a conglomerate of over 15 QSR franchises, including Cold Stone Creamery and Blimpie Subs. He later worked on developing QSR concepts for Revamp Corp. in Tokyo. After returning to the U.S., he served as president of Daily Jam, a limited-service breakfast and brunch chain. He holds a bachelor’s degree in business administration in finance from Fort Lewis College.

Patrick Moroney is the Director of Real Estate Acquisitions for Zoned Properties. Previously, he was one of the most successful Associate Brokers at Kidder-Mathews, focusing primarily on the regulated cannabis industry. He also worked as a commercial real estate broker rep at Cushman & Wakefield and Colliers International. He graduated from Arizona State University, after which he spent four years as a local sports broadcaster in Georgia and Iowa.

Kyle Gere is the Director of Advisory Services at Zoned Properties. He has years of licensing experience across multiple U.S. states in the medical and recreational cannabis markets. Since 2015, he has been involved in cannabis real estate transactions in Arizona and Michigan, managing a portfolio of medical marijuana properties. He attended Northern Arizona University, graduating with a bachelor’s degree in business administration in both management and marketing.

Zoned Properties Inc. (OTCQB: ZDPY), closed Monday's trading session at $0.6, up 16.0542%, on 1,360 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$0.80.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom, a global leading provider of traditional and digital identity solutions, recognizes the growing domestic violence ("DV") cases and looks to remedy it through its innovative electronic monitoring ("EM") solutions

DV cases in the US have posted an unfortunate 8.7% growth since 2019, primarily attributed to the lack of accountability and the overall lack of proactivity from law enforcement in dealing with offenders

With incarcerations having proven ineffective in reducing these numbers, there has been a move toward EM adoption, which, with the right technologies, has yielded impressive results

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, is aware of the growing domestic violence cases and believes it has the technology to help remedy the situation. So far, its electronic monitoring ("EM") solutions have proven themselves in monitoring and holding domestic violence offenders accountable for their actions in a variety of markets, including the U.S.

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Monday's trading session at $0.4004, up 45.0725%, on 127,579,463 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1524/$1.5394.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. "A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas… Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (‘GBM') treatment, saying, ‘I have been intrigued by the company's pivotal trial design for Berubicin and was further compelled by the successful outcome from the recent interim analysis, the rapid pace of enrollment, and strong management team,'" a recent article reads. "Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. Berubicin, an anthracycline, appears to cross the blood-brain barrier and kill cancer cells, as results from the completed Phase 1 human clinical trial show. The trial demonstrated positive responses that included one durable complete response."

To view the full article, visit https://ibn.fm/EpZA0

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.2441, up 0.287592%, on 117,917 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.22/$4.40.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

A growing number of corporations in the United States and other nations are using artificial intelligence ("AI") technology to enhance their environmental, social and governance ("ESG") reporting and tackle the increasingly dire issue of climate change. Despite being in its infancy, the nascent AI industry has attracted significant attention due to its potential to disrupt several industries significantly. Generative AI-powered tools such as ChatGPT have been especially popular in corporations in recent years as the AI can help companies supercharge their ESG reporting and enhance their climate-change mitigation efforts to meet increasingly stringent corporate sustainability requirements. Josh Hatch from Brightworks Sustainability says his company began its journey in sustainability consulting before transitioning to green-building work because it generally has a significant impact on sustainability. The company now dabbles in ESG as well by aiding in bottom-up ESG implementation in corporate policies and facilities. AI technology is a great complement to other initiatives, such as the extraction of green-energy metals that companies such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) are focusing on because renewable energies such as wind and solar are a big part of ensuring sustainability.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Monday's trading session at $0.0659, up 3.0493%, on 35,000 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.134.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

An American appeals court has backed the Environmental Protection Agency's (EPA) decision to allow the state of California to set its own electric vehicle emissions standards. A three-judge panel rejected a challenge issued by 17 GOP-led states and entities that produce or sell liquid fuels and ruled that California can establish its electric vehicle requirements and emission limits, per the EPA's decision. In 2019, former President Donald Trump revoked California's ability to set its tailpipe emission limits and zero-emission car-sales mandates through 2025. The EPA reversed President Trump's decision in March 2022, several months after President Joe Biden took office. The U.S. Court of Appeals for the District of Columbia has now ruled in the EPA's favor and supported its decision to reverse former President Trump's decision. As the emissions restriction timelines set by California come into force, more motorists are likely to buy EVs from startups such as Mullen Automotive Inc. (NASDAQ: MULN); in addition, other states could also copy those vehicle transition targets.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $3.23, off by 14.2098%, on 958,841 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.19/$2686.50.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Climate impact concerns are a defining issue, not only in the U.S. but around the world, with a new generation of innovators seeking to learn from past mistakes and better address the need for clean energy solutions

Distributed energy solutions company Correlate Energy Corp. is successfully focusing on the most cost effective and efficient solar energy installation opportunities and clean energy infrastructure optimization

As part of this, the company is also optimizing a renewable revenue stream by carefully retaining ownership of some of its energy systems while acquiring other renewable energy companies with proven capabilities

The company's average contract size is now about $2 million, and CIPI currently has about $150 million in-progress projects in various stages of development

Planetary climate change is increasingly viewed as the single most over-arching technological issue in need of a worldwide solution, but efforts to innovate and advance solutions are hampered by the need for cost-effective and workable startup-enterprise financing models. In spite of initial challenges and missteps, progress is accelerating in the development of viable green solutions and associated business and financial models. In his analysis on innovation, Forbes Technology Council member Steve Smith recently argued that business investment in "this transformative field" must be more responsive to real-world conditions, such as the intermittent availability of wind and solar power sources, the imbalance between peak user demand and peak energy-generation, and the need to ensure that potential customers are motivated (https://ibn.fm/OPjYe). Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is advancing its superior cost-effective solutions for making solar power and other green energy solutions accessible from the ground up — working with baseline consumers and mid-tier companies that are often overlooked by larger forces in the sustainability market. Most of the company's clients have portfolios with dozens of locations across the country that may need Correlate's services.

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Monday's trading session at $1.42, off by 2.7397%, on 2,357 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3501/$2.35.

Recent News

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF)

The QualityStocks Daily Newsletter would like to spotlight Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) .

Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF), a leading gold explorer in the Guiana Shield, is reporting on additional drill results from its infill drill program at the Oko West Project. Highlights of the report include Hole D-375 intersecting 60.4 meters ("m") @ 1.50 grams per tonne of gold ("g/t") Au, including 6.0 m @ 7.06 g/t, Hole D-381 intersecting 44.9 m @ 2.28 g/t Au, including 18.3 m @ 4.38 g/t Au and Hole D-389 intersecting 21.6 m @4.00 g/t Au, including 4.0m @ 17.67 g/t Au. According to the report, these results continue to expand the core of high-grade mineralization that has been identified at Block 6 of the wholly owned project; the results are also consistent with the results of the previously released hole D-380, which intersected 39.7 meters at 5.27 grams per tonne of gold including 3.8 m @ 14.18 g/t Au and 13.0 m @ 10.50 g/t Au. "We are pleased to see the identification of further high-grade mineralized shoots at Oko West, resulting from the exploration team's growing understanding of structural controls and the factors that are localizing mineralization along the Kartuni shear zone," said Reunion Gold CEO Rick Howes in the press release. "These latest results continue to indicate the potential for additional high-grade gold mineralization to be defined even within areas of existing wider drill spacing as our current infill program continues."

To view the full press release, visit https://ibn.fm/OQPt5

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) is a leading gold explorer in the Guiana Shield, South America. In early 2021, the Company announced an exciting new greenfield gold discovery at its Oko West project in Guyana, where, after 22 months of resource definition drilling, the Company has announced an initial Mineral Resource Estimate (MRE) containing 2.475 Moz of gold in Indicated resources at 1.84 g/t and 1.762 Moz of gold in inferred resources at 2.02 g/t contained within a pit shell outline. Preliminary metallurgy results performed by the company, consisting of 8 bottle roll tests obtained strong results, averaging just under 90% recoveries on average. The Company is continuing with additional development activities at Oko West, including environmental base line studies and additional metallurgical work relating to the delivery of a PEA by year end 2023. In addition, Reunion Gold is currently exploring several priority targets in the Oko West project area on which the company feels there is good potential to add additional resource ounces. This includes the opportunity to grow the initial mineral resource estimate (MRE) released on June 13, 2023, and to discover additional gold ounces at Oko West outside of the resource area.

The Guiana Shield remains one of the most prospective exploration locations globally for the discovery of world class orogenic gold deposits. The shield, including both Guyana and Surinam, contain large relatively underexplored greenstone belts, from which Reunion Gold expects many more significant gold discoveries could emerge in the coming years.

Oko West Project

Reunion Gold’s Oko West Project is a brand-new gold discovery in northwest Guyana located within the historical Oko gold district. Alluvial gold has been mined from the Oko district since the turn of the century, but very little primary gold has been mined or even explored for to the best of the company’s knowledge. The project comprises a prospecting license with an area of approximately 44 square kilometers and is 100% held by Reunion’s Guyanese subsidiary.

In 2020, Reunion Gold’s geochemical survey, trenching and initial 1000 m drill program discovered and confirmed the presence of gold mineralization in this Orogenic gold system. The gold occurs in the eastern edge of the project area, along a 6km long sheared contact between a granitoid intrusion and a meta volcanic-meta sedimentary rock package. The MRE is located within the Kairuni zone, which represents the northern most 1.9 km of the 6 km long contact.

“We are advancing our Oko West project along two tracks. The first is to advance the exploration programs outside of the Kairuni zone, aimed at outlining and discovering additional gold mineralization within our Prospecting License. On this front, I am very excited by the results from the initial Scout RC Geochem drill program that is defining new targets west of our Kairuni zone,” Rick Howes, President and CEO of Reunion Gold, stated in a recent news release. In addition to the targets west of the Kairuni zone, the company has also commenced exploration work on the southern ~ 4 km of the same sheared contact that hosts the Kairuni zone MRE. In addition, the company feels that the MRE marks the size of the Kairuni resource at a point in time and that there is good potential to continue to grow the resource. The MRE remains open at depth below the resource pit outline in the block 4 area and also to depth and along strike in the block 5 and 6 areas. In addition to the exploration programs, the second strategic track is to rapidly advance the Kairuni zone along the path to development. To that end the company is moving forward with the engineering and other studies, including more detailed metallurgical studies, that will support the release a PEA on the Kairuni zone by year end 2023 The company feels that the rapid advancement of development of Kairuni zone MRE, while in parallel continuing to explore for additional ounces on the project, is the best path to try and maximize shareholder value in the shortest period of time.

Guyana

Guyana boasts a long history of mining gold, bauxite, diamonds and manganese. Still, the greenstone belts of the Guiana Shield remain relatively unexplored when compared to the analogous regions of the West African Shield (Birimian), which, according to geological evidence, was once connected to the Guiana Shield, forming a contiguous craton prior to the Mesozoic period.

Despite a historical lack of accessibility and low exploration intensity, several significant large-scale projects have emerged in the Guiana Shield, including Aurora, Oko West, Oko Main, Toroparu and Omai. Guyana is English speaking with a British based parliamentary and legal system and boasts the world’s fastest growing economy on the back of significant offshore oil discoveries by Exxon and its partners. It is expected that a significant amount of the revenues from oil production will be invested in improving the infrastructure, education and health care and agriculture within the country.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, called 2022 the “strongest year for gold demand in over a decade.” Annual gold demand jumped 18% YoY due to “colossal central bank purchases, aided by vigorous retail investor buying and slower ETF outflows.”

Despite this spike in demand, total annual gold supply increased by just 2% in 2022, halting two years of successive declines but failing to challenge 2018 highs. This supply-demand imbalance could provide a favorable market environment as Reunion Gold continues to advance drilling programs at its 100%-owned Oko West Project.

Management Team

Successful exploration and the discovery of significant deposits in any given region require immense amounts of local knowledge and experience. This is the principle around which Reunion Gold has built its management team. In total, the company’s leadership boasts over 225 years of combined experience in the Guiana Shield.

David Fennell is the Executive Chairman of Reunion Gold, a position he has held since the company’s inception in 2003. He has 40 years of experience in the mining industry. He received a law degree from the University of Alberta in 1979 and practiced law until he founded Golden Star Resources Ltd. in 1983. During his term as President and CEO, Golden Star became one of the largest and most successful exploration companies. While at Golden Star, he was instrumental in the discovery and development of the Omai Gold Mine in Guyana and the Gross Rosebel Mine in Suriname. In 1998, Mr. Fennell became Chairman and CEO of Hope Bay Gold Corporation. He held this position through the merger of Hope Bay and Miramar Mining Corporation and remained as Executive Vice-Chairman and Director for the combined entity until its takeover by Newmont Mining Corporation in 2008. Mr. Fennell is currently a member of the board of directors of G Mining Ventures Corp. and Sabina Gold & Silver Corp.

Rick Howes, P.Eng., is the company’s President and CEO. He is a seasoned mining executive with over 39 years of experience in the mining industry, most recently as CEO of Dundee Precious Metals. Mr. Howes has extensive operating, technical and project development experience in both underground and open pit mines throughout Canada and internationally. In 2009, Mr. Howes joined Dundee Precious Metals, where, as VP and General Manager, he led the transformation of the Chelopech Mine in Bulgaria to reach world-class levels of performance. He became COO in 2011 and oversaw several significant growth capital development projects, including the expansion of the Chelopech Mine, the upgrade and expansion of the Tsumeb Smelter in Namibia and the development of the greenfield Ada Tepe open pit gold mine in Bulgaria. He was appointed CEO in April 2013, leading Dundee’s transformation from a junior gold producer to a multi-asset mid-tier gold producer generating strong free cashflow and solid returns to shareholders. Mr. Howes has been recognized as a visionary leader in mining, organizational innovation and transformation and was recognized as the Outstanding Innovator of 2016 by the International Mining Technology Hall of Fame.

Alain Krushnisky is the CFO of Reunion Gold. He brings to the company years of experience in the mining sector, including 10 years with Cambior Inc. (now IAMGOLD) in capacities such as Vice-President and Controller. Since 2004, Mr. Krushnisky has been doing consulting work for various publicly listed exploration and mining companies. He graduated from the University of Ottawa in 1983 with a bachelor’s degree in commerce and is a Chartered Professional Accountant.

Justin van der Toorn is the company’s VP Exploration. He is an exploration geologist with 18 years’ experience in the minerals industry, leading and managing exploration teams from grassroots activities through to discovery and resource definition drilling. Mr. van der Toorn’s previous experience has been in a range of commodity and deposit styles, including extensive work in Carlin-style gold, low- and high-sulphidation epithermal, porphyry and orogenic gold systems. He holds an MSci degree in Geological Sciences from the Royal School of Mines, Imperial College London. He is registered as a Chartered Geologist (CGeol) of the Geological Society, and a European Geologist (EurGeol) by the European Federation of Geologists.

Doug Flegg is the company’s business Development advisor. Doug has over 35 years’ experience in mining and mining finance with senior positions in research, portfolio management and global equity sales. Previously, Mr. Flegg was Managing Director Global Mining Sales with BMO Capital Markets where he was involved in raising $35 billion in over 200 corporate financings. Since 2016 he has been providing business development, strategic, and financing advice to corporate mining clients. Mr. Flegg also has a B.Sc. in Geology, work experience as a geologist and an MBA from Queens University.

Reunion Gold Corp. (OTCQX: RGDFF), closed Monday's trading session at $0.348, off by 7.7413%, on 111,308 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.24/$0.46.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Multiple sclerosis (MS) is a chronic illness that affects an individual's central nervous system. The disease manifests differently in each individual and has varying trajectories, which makes it difficult to manage. It also has no cure. New research has identified three subtypes of the disease based on immune markers observed in participants' blood. For the research, a team of investigators led by Professor Heinz Wiendl, a professor at the University of Münster, conducted a comprehensive analysis of the immunological properties of different blood samples collected from more than 300 early multiple sclerosis patients and a validation group made up of 232 patients with the same illness. In both groups, the researchers determined that cellular immune signatures split into three separate subtypes: E1, E2 and E3. It is noteworthy that many other entities, such as Clene Inc. (NASDAQ: CLNN), are focusing on developing next-generation treatments for MS. It is just a matter of time before patients have access to affordable treatment options that will offer them better clinical outcomes compared to the current medications.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Monday's trading session at $0.3314, off by 7.8677%, on 648,201 volume. The average volume for the last 3 months is 623,779 and the stock's 52-week low/high is $0.25/$1.09.

Recent News

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBR Safe (NASDAQ: SOBR) ("SOBRsafe"), a disruptive company leveraging advanced alcohol detection approaches and technologies, recently published three case studies that empirically demonstrate the performance of its alcohol screening technology, SOBRcheck(TM), based on customer data, experiences and results. "A stationary identification and alcohol screening/monitoring technology launched in 2021, SOBRcheck detects and instantaneously reports the presence of alcohol emitted through the pores of a fingertip. It is equipped with a biometric identifier that automatically confirms the user's identity and hardcodes this identification information, as well as the date and time of the screening, into the automatically generated reports, thus boosting reliability," a recent article reads. "SOBRcheck can be used at the entry points of job sites, as TerraTech Services, a national leader in oilfield services and logistics, has done since November 2022, following a successful pilot program… SOBRcheck can also be deployed to replace traditional breathalyzer tests, which require dedicated staff – because they have to be manually administered – and are expensive, cumbersome, time-consuming, and unhygienic. For instance, Big Horn, Montana's sixth largest county in landmass, which previously used traditional breathalyzer tests for its 24/7 Sobriety Program, turned to SOBRsafe in July 2023, initially deploying the SOBRcheck technology in two locations within the County building. Since deployment, the screening has followed – and still follows – an unstaffed testing procedure in which each participant simply completes their alcohol screen in about 10 seconds… SOBRcheck delivers in 10 seconds what the observed screening procedure using a traditional breathalyzer would deliver in 45 seconds, with the high number of screens compounding the time savings."

To view the full article, visit https://ibn.fm/VNTgy

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Monday's trading session at $0.3023, off by 8.9458%, on 80,139 volume. The average volume for the last 3 months is 118,867 and the stock's 52-week low/high is $0.2004/$2.33.

Recent News

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Experts project demand for copper is set to rise in coming years

Increased demand from power generation, EVs and electronic devices may push the copper supply deficit to 6.5 million MT

"We are excited about this significant exploration program at Storm," said Aston Bay CEO Thomas Ullrich

In a space projected to see significant growth and demand in the coming decade, Canadian minerals exploration company Aston Bay Holdings (TSX.V: BAY) (OTCQB: ATBHF) is focused on establishing a strong foothold. As an explorer of high-grade copper and gold deposits in North America, the company is beginning an aggressive exploration program focused on immediate resource growth and testing of large-scale copper exploration targets (https://ibn.fm/rQ59y).

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Monday's trading session at $0.0952, off by 5.966%, on 45,000 volume. The average volume for the last 3 months is 57,163 and the stock's 52-week low/high is $0.0216/$0.2474.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.